This is bad news for vaccine makers, who expected to get a large sales bump from the H1N1 vaccine. In October, analysts estimated that GlaxoSmithKline Plc would earn an extra $1.62 billion from the vaccine while Novartis AG had forecast H1N1 sales of $400 to $700 million for the period.
Germany and France are just two of the countries that have announced the cancellation of vaccine orders.
About EQUITIES:
Since 1951, EQUITIES Magazine has been a leading media company providing business editorial content designed to serve the needs of business leaders, professionals, institutional investors and retail investors. We are focused on business and the business of making money, not on lifestyle subjects. We publish original reporting in print and on our website, as well as select content at www.nasdaq.com. For 28 years we have hosted our own branded investor conferences that connect public company CEO’s with our loyal readers in the investment community.
Sign up for a free one-year subscription to EQUITIES Magazine
